Systemic therapy of non-resectable metastatic melanoma

9Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy. © 2010 by the authors; licensee MDPI, Basel, Switzerland.

Cite

CITATION STYLE

APA

Orouji, A., Goerdt, S., & Utikal, J. (2010, June). Systemic therapy of non-resectable metastatic melanoma. Cancers. https://doi.org/10.3390/cancers2020955

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free